Ixazomib, Cyclophosphamide, and Dexamethasone for Previously Untreated Light Chain Amyloidosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
Blood Adv 2022 Jun 23;[EPub Ahead of Print], E Muchtar, MA Gertz, B LaPlant, F Buadi, N Leung, P O'Brien, PL Bergsagel, A Fonder, YL Hwa, M Hobbs, DK Helgeson, EE Bradt, WI Gonsalves, MQ Lacy, P Kapoor, M Siddiqui, JT Larsen, R Warsame, SR Hayman, RS Go, D Dingli, TV Kourelis, A Dispenzieri, SVV Rajkumar, SK KumarFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.